You can buy or sell RTTR and other stocks, options, ETFs, and crypto commission-free!
Ritter Pharmaceuticals, Inc. engages in the development of novel therapeutic products which modulate the human gut microbiome to treat gastrointestinal diseases. It focuses on the development and commercialization of RP-G28. Read More The company was founded by Andrew J. Ritter and Ira E. Ritter on March 29, 2004 and is headquartered in Los Angeles, CA.
Los Angeles, California
52 Week High
52 Week Low
Ritter Pharmaceuticals Completes Dosing of Last Patient in Pivotal 557-Subject Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance
Top-line Data Readout on Target for early Q4 2019 LOS ANGELES, May 07, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq:RTTR) ("Ritter Pharmaceuticals" or the "Company"), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases, today announced that the final patient in its first pivotal Phase 3 clinical trial of RP-G28 for the potential treatment of Lactose intolerance (LI), a study known as the "Liberatus" study (NCT03597516), h...
Simply Wall StApr 25
Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR): What Are The Future Prospects?
The most recent earnings update Ritter Pharmaceuticals, Inc.’s (NASDAQ:RTTR) released in December 2018 showed company earnings became less negative compared to the previous year’s level – great news for investors Below, I’ve laid out key numbers on how market analysts predict Ritter Pharmaceuticals’s earnings growth trajectory over the next few years and whether the future looks brighter. Note that I will be looking at net income excluding extraordinary items to get a better understanding of the underlying ...
-$0.72 per share
Expected May 24, After Hours